Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Executive Summary
The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable
You may also be interested in...
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
The fuzzy regulatory picture for the challenging obesity space is about to come into focus with two actions from FDA: the agency is expected to issue final guidance on weight management drug development soon and, later, may consider requirements for proof of cardiovascular safety, in the vein of the recent guidance on diabetes drugs
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
The fuzzy regulatory picture for the challenging obesity space is about to come into focus with two actions from FDA: the agency is expected to issue final guidance on weight management drug development soon and, later, may consider requirements for proof of cardiovascular safety, in the vein of the recent guidance on diabetes drugs
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
In wake of rimonabant, formal evaluation of depression will probably be needed for centrally acting drugs.